Clinical Performance
As TruScreen’s results come from an objective, self-checking digital system, they are free from the highly subjective human judgment required for cellular diagnosis on conventional screening methods, such as Pap Smears.
The TruScreen device has now been clinically validated by over 30 published trials to date, with large clinical studies including over 40,000 women in multiple settings.
A large number of clinical evaluations and trials are conducted in our key markets, and are generally only available in the native language of the publication’s region - but below are a number of English and Chinese-language published papers that are available in the public domain.
2024
Saudi Arabia
507 patients
2024
Guangdong, China
489 patients
2023
Liaoning, China
Study on the role of TruScreen Screening Technology in Cervical Cancer Screening
997 patients
2023
Beijing, China
318 patients
2022
Sichuan, China
Accuracy of TruScreen in the Early Diagnosis of Cervical Precancerous Lesions in Outpatients in Sichuan Province
1319 patients
2022
Beijing, China
The clinical value of TruScreen in cervical cancer screening
476 patients
2022
Shanghai, China
A comparative study of photoelectric screening system Truscreen and colposcopy in cervical lesions screening
283 patients
2021
Shanghai, China
458 patients
2021
Shanghai, China
Clinical value of TruScreen in early diagnosis of cervical cancer and precancerous lesions: a hospital-based multicenter study
974 patients
2020
Hunan, China
Comparison study in hospital opportunistic screening for cervical cancer
192 patients
2020
Fujian, China
Clinical Analysis of TruScreen and LBC in Cervical Cancer Screening
683 patients
2020
Hunan, China
1344 patients
2019
Hebei, China
The Clinical Effectiveness of Cervical Cancer Screening System TruScreen in Cervical Cancer Screening
320 patients
2019
Beijing, China
Clinical Observation of Cervical Cancer Screening System TruScreen in 1030 Cases
130 patients
2019
Henan, China
Application Value of TCT, HPV and TruScreen in Screening Cervical Disease
318 patients
2013
Beijing, China
Evaluation of real time optoelectronic device TruScreen in cervical cancer screening
391 patients
2011
Guangdong, China
Clinical research on fluorescence microscopy technology combined with cervix pap smear in cervical cancer screening
500 patients
2011
Poland
293 patients
2010
Shandong, China
The application value of cervical cancer screening system and thinprep cytological test in the screening of cervical lesion during the women’s health screenings
532 patients
2010
Guangdong, China
392 patients
2008
Poland
147 patients